This study investigated the influence of baseline and worsening renal function (WRF) on the efficacy of spironolactone in patients with severe heart failure (HF).
Background
Renal dysfunction or decline in renal function is a known predictor of adverse outcome in patients with HF, and treatment decisions are often on the basis of measures of renal function.
Methods
We used data from the RALES (Randomized Aldactone Evaluation Study) in 1,658 patients with New York Heart Association functional class III or IV HF and an ejection fraction Ͻ35%. Participants were randomized to spironolactone 25 mg, which could be titrated to 50 mg, or placebo daily. Renal function (estimated glomerular filtration rate [eGFR] ) was estimated by the Modification of Diet in Renal Disease equation. Worsening renal function was defined as a 30% reduction in eGFR from baseline to 12 weeks post-randomization.
Results
Individuals with reduced baseline eGFR exhibited similar relative risk reductions in all-cause death and the combined endpoint of death or hospital stays for HF as those with a baseline eGFR Ͼ60 ml/min/1.73 m 2 and greater absolute risk reduction compared with those with a higher baseline eGFR (10.3% vs. 6.4%). Moreover, WRF (17% vs. 7% for spironolactone and placebo groups, p Ͻ 0.001) was associated with an increased adjusted risk of death in the placebo group (hazard ratio: 1.9, 95% confidence interval: 1.3 to 2.6) but not in those randomized to spironolactone (hazard ratio: 1.1, 95% confidence interval: 0.79 to 1.5, p interaction ϭ 0.009). The risk of hyperkalemia and renal failure was higher in those with worse baseline renal function and those with WRF, particularly in the spironolactone arm, but the substantial net benefit of spironolactone therapy remained.
Conclusions
The absolute benefit of spironolactone was greatest in patients with reduced eGFR. Worsening renal function was associated with a negative prognosis, yet the mortality benefit of spironolactone was maintained. Elevated aldosterone concentrations have known detrimental effects on the myocardium and renal vasculature (1) . Two pivotal clinical trials in heart failure (HF) have demonstrated benefit with aldosterone receptor antagonists (2, 3) , and current HF treatment guidelines recommend the use of a mineralocorticoid receptor antagonist (MRA) in patients Hospitalization and Survival Study in Heart Failure) further supported the use of these agents in HF patients with milder HF symptoms (6) . Mineralocorticoid receptor antagonists are not recommended when the serum creatinine is raised above 2.5 mg/dl (or when creatinine clearance is Ͻ30 ml/min) or in those with serum potassium levels above 5.0 mmol/l. Renal dysfunction, even transient, is common in HF patients and is a known predictor of cardiovascular outcomes and mortality in patients with cardiac disease. Worsening renal function (WRF), otherwise known as cardiorenal syndrome type 2 (7), is defined as increases in creatinine or reductions in estimated glomerular filtration rate (eGFR). Worsening renal function has been associated with adverse outcomes in patients with HF, underuse of proven agents, and even discontinuation of beneficial medication (8, 9) .
Nevertheless, rises in creatinine or declines in eGFR are common in patients receiving inhibitors of the reninangiotensin-aldosterone system, possibly due to alterations in renal hemodynamic status (10) . In both the Survival And Ventricular Enlargement (11) and Studies of Left Ventricular Dysfunction (12) trials, worsening creatinine was not associated with adverse outcome in patients receiving the angiotensin-converting enzyme inhibitor (ACEI) captopril, whereas it was associated with increased risk in those receiving placebo. Recent data in post-MI patients from the EPHESUS (Eplerenone PostAcute Myocardial Infarction Heart Failure Efficacy and Survival Study) showed that early WRF with eplerenone was associated with an increased risk of adverse cardiovascular outcomes, yet the benefit of eplerenone was maintained (13) . The prognostic significance of WRF in patients with moderate to severe HF receiving spironolactone, however, remains unknown.
We used data from the RALES (Randomized Aldactone Evaluation Study) to determine the influence of baseline renal function on efficacy of the MRA spironolactone in HF patients and the prognostic importance of WRF in HF patients receiving an aldosterone antagonist. We hypothesized that WRF would be associated with a more benign prognosis in patients receiving an MRA compared with patients receiving placebo.
Methods
Participants. The RALES study was a double-blind, randomized, placebo controlled trial that was designed to assess the efficacy of spironolactone on prevention of all-cause mortality and cardiac-related hospital stays in patients with New York Heart Association functional class III or IV HF. Participants were enrolled if they had a left ventricular ejection fraction Ͻ35% while taking background ACEIs and diuretics. Exclusion criteria were primary valvular disease, congenital heart disease, unstable angina, liver failure, listing for cardiac transplant, active cancer, or any other life-threatening disease. Patients with serum creatinine Ͼ2.5 mg/dl or potassium Ͼ5 mmol/l were also excluded. Participants were randomized to receive spironolactone 25 mg or placebo daily. After 8 weeks, the dose could be increased to 50 mg daily for patients with signs and symptoms of progression of HF without evidence of hyperkalemia. Serum potassium and creatinine were measured at 4, 8, and 12 weeks during the titration phase and every 3 months thereafter during the study and were available in 1,658 of the 1,663 patients enrolled in the study. Concomitant treatment with digoxin and vasodilators was allowed, and the use of potassium-sparing diuretics was not permitted. Oral potassium supplement use was discouraged unless hypokalemia (defined as a serum potassium concentration of Ͻ3.5 mmol/l) developed. Statistical analyses. We defined reduced baseline eGFR as Ͻ60 ml/min/1.73 m 2 and WRF as a 30% reduction in eGFR (14) and between those with WRF and those without WRF were compared with identify potential differences. Betweengroup assessments were performed with t tests for continuous variables and chi-square or Fisher exact tests, as appropriate, for categorical variables. Hyperkalemia was defined as a potassium level Ն5.5 mmol/l at any visit or a serious adverse event related to hyperkalemia at any time during study follow-up. For WRF, we performed a sensitivity analysis with another definition of Ͼ0.3 mg/dl increase in serum creatinine with qualitatively similar results (not shown). Cox proportional hazards regression models were used to examine associations between baseline renal function and all-cause mortality and the combined endpoint of death or HF hospital stay as well as the effectiveness of treatment with spironolactone. Paired t-tests were used to assess differences in eGFR by treatment arm during the titration phase. A WRF during the titration phase (through week 12) was related to subsequent long-term outcomes in a landmark analysis. We further performed these analyses, adjusting for the following covariates: age, sex, race, HF etiology, history of diabetes, MI, angina, hypertension, baseline blood pressure, ejection fraction, baseline potassium and creatinine, treatment, baseline medications (aspirin, ACEI/ angiotensin receptor blocker [ARB], beta-blocker, loop diuretic, digoxin), and eGFR or WRF ϫ treatment inter- Vardeny et al. November 13, 2012 November 13, :2082 Spironolactone and Renal Dysfunction in HF action term. All analyses were conducted with Stata (version 11, StataCorp, College Station, Texas).
Results
Of 1,658 patients included in these analyses, 792 (48%) had a baseline eGFR Ͻ60 ml/min/1.73 m 2 , and 866 (52%) had a baseline eGFR Ն60 ml/min/1.73 m 2 . Baseline characteristics by eGFR are shown in Table 1 . Participants with a baseline eGFR Ͻ60 ml/min/1.73 m 2 were older, more likely to be female, diabetic, Caucasian, and were more likely to have an ischemic etiology for HF and less likely to be taking aspirin, diuretics, and digoxin at study entry.
WRF occurred in 199 (12%) patients during titration ( Table 2 ). The percentage of patients with WRF was significantly higher in the spironolactone group than in the placebo group (17% vs. 7%, p Ͻ 0.001). Although eGFR was similar in the spironolactone and placebo groups at baseline (65. Renal function continued to decline in both groups; however, differences in eGFR between spironolactone and placebo groups were no longer significant by 6 months after randomization. The proportion of patients with WRF was similar in those who started with baseline eGFR below and above 60 ml/min/1.73 m 2 (11% vs. 15%, p ϭ 0.22). Patients with worsening eGFR were older and more likely to be female. There were no significant differences in baseline characteristics between the placebo and spironolactone groups in patients with or without WRF. Of note, blood pressure at the end of titration (week 12) was not different between participants with and without WRF. In addition, patients with WRF were more likely to have received ACEIs or ARBs (34% vs. 26%, p ϭ 0.01), digoxin (22% vs. 14%, p ϭ 0.004), or loop diuretics (41% vs. 33%, p ϭ 0.02) during titration, although this did not differ by treatment group. Outcomes by baseline eGFR and WRF. Baseline eGFR lower than 60 ml/min/1.73 m 2 was associated with similarly increased risk for mortality in both treatment groups (Fig. 1A, Table 3 ), even adjusting for baseline covariates. The risk for the combined endpoint of death or HF hospital stay was similarly increased in crude estimates in both groups (Fig. 1B, Table 3 ) but not significantly different when adjusted for baseline covariates. There were a total of 670 deaths (386 placebo, 284 spironolactone), similarly distributed between eGFR Ͻ or Ն60 ml/min/1.73 m 2 (402 vs. 436 deaths). For the combined endpoint of all-cause death or HF hospital stays, there were 909 events (522 placebo, 387 spironolactone); 483 for eGFR Ͻ60, and 422 for those with eGFR Ն60 ml/min/1.73 m 2 . At the end of titration (12 weeks), 63 deaths occurred in the placebo group, and 54 deaths occurred in the spironolactone group. For HF hospital stays, 105 occurred in the placebo group, and 51 occurred in the spironolactone group by the end of titration. When stratifying by baseline eGFR, 80 deaths occurred in eGFR Ͻ60, and 37 occurred in those with eGFR Ն60. For HF hospital stays, 74 occurred in eGFR Ͻ60, whereas 81 occurred in eGFR Ն60. Baseline renal function, modeled as a continuous or categorical variable, did not modify the benefits of spironolactone, with an approximately 30% relative risk reduction for mortality regardless of baseline eGFR, and a similar risk reduction for the combined endpoint of death or HF hospital stay (Fig. 1A, Table 4 ). The absolute risk reduction for mortality was substantially higher in patients with worse baseline eGFR (10.3% vs. 6.4%), and the absolute risk reduction for death or HF hospital stay at 2 years was 13.7% in the lower eGFR group, compared with 12.7% in the higher eGFR group.
Worsening renal function, defined as a 30% reduction in eGFR during the titration period, was associated with an increased subsequent long-term risk of death in the placebo group, even when adjusted for baseline covariates (hazard ratio: 1.9, 95% confidence interval [CI]: 1.3 to 2.6) (Figs. 2A and 2B, Table 3 ). In contrast, in the spironolactone arm, WRF was not associated with an increased risk for death, with a highly significant interaction between treatment and WRF with respect to outcome (hazard ratio: 1.1, 95% CI: 0.79 to 1.5; p interaction ϭ 0.009). For the combined outcome of death or hospital stay for HF (Figs. 2C and 2D , Table 3 ), WRF was similarly associated with a significantly increased risk in the placebo group, and this risk was also substantially attenuated in the treatment arm (p-interaction 0.04). Patients randomized to spironolactone derived ben- Values are mean Ϯ SD or %. *Estimated glomerular filtration rate (eGFR) is in ml/min/1.73 m 2 . ACEI ϭ angiotensin-converting enzyme inhibitor; ARB ϭ angiotensin receptor blocker; BP ϭ blood pressure; EF ϭ ejection fraction; Kϩ ϭ potassium supplement; MI ϭ myocardial infarction; NYHA ϭ New York Heart Association functional class; SCr ϭ serum creatinine. efit whether or not renal function worsened during titration, with no attenuation of the approximately 30% reduction in mortality, and mild attenuation in the combined endpoint, when making even the most conservative comparison between the treatment group with WRF and the placebo group without WRF (Fig. 2, Table 4 ). Hyperkalemia or adverse event rates by baseline eGFR and WRF. Hyperkalemia defined as potassium Ͼ5.5 mmol/l at a study visit or a hyperkalemia adverse event at any time during follow-up occurred more frequently in participants with reduced baseline eGFR and particularly more frequently in those with reduced eGFR who received spironolactone compared with those with reduced eGFR receiving placebo (25.6% vs. 8.5%, p Ͻ 0.001) ( Table 5 ). The increased risk of hyperkalemia due to spironolactone was higher in those with lower eGFR compared with those with higher eGFR (odds ratio: 1.53, 95% CI: 1.16 to 2.02). Those with baseline eGFR Ͻ60 who were taking spirono- Values are mean Ϯ SD or %. *Comparison between no worsening renal function (WRF) and WRF groups. Spiro ϭ spironolactone; other abbreviations as in Table 1 .
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Patients with WRF had a higher overall risk of hyperkalemia, and this risk was even greater in those receiving spironolactone compared with those who received placebo (Table 5 ). The increased risk of hyperkalemia in patients receiving spironolactone was most evident if renal function worsened (odds ratio: 3.6, 95% CI: 1.5 to 8.6, compared with participants receiving spironolactone without WRF). Finally, patients with WRF were more likely to have their study drug dose reduced or discontinued during the titration period, although this also appeared true whether they were receiving placebo or spironolactone.
Discussion
In this analysis of patients with moderately severe to severe HF randomized to an MRA or placebo, individuals with reduced baseline eGFR exhibited similar relative risk reductions in all-cause death and the combined endpoint of death or hospital stays for HF as those with a baseline eGFR Ͼ60 ml/min/1.73 m 2 and greater absolute risk reduction compared with those with a higher baseline eGFR. Moreover, WRF-defined in this study as a 30% reduction in baseline eGFR-was associated with an increased risk of death in the placebo group but not in those randomized to spironolactone, and the risk of the combined endpoint of death or HF hospital stay in those with WRF was increased in the placebo group but markedly attenuated in those receiving spironolactone. The risk of hyperkalemia was higher in those with worse baseline renal function and those with WRF, particularly in the spironolactone arm, but there remained substantial net benefit.
Spironolactone was associated with an approximate 30% reduction in all-cause mortality in the RALES study, and the more selective MRA eplerenone has shown similar benefit in several other studies. In this analysis, we noted a similar relative benefit and greater absolute benefit in patients with baseline eGFR Ͻ60 ml/min/1.73 m 2 treated with spironolactone, a finding that is similar to that observed in post-MI patients with lower eGFR treated with an ACEI (15) and in a small study suggesting improvement in myocardial systolic and diastolic left ventricular function in patients with chronic kidney disease when an MRA was used in addition to ACEIs or ARBs (16, 17) . Although we observed an increased risk of adverse events, particularly hyperkalemia, in these patients, there was still a substantial net benefit to the use of MRAs in HF patients with reduced eGFR.
Although WRF during the titration phase occurred more frequently in patients randomized to spironolactone, the risk associated with this worsening was greatest in patients in the placebo group and was markedly attenuated in those taking spironolactone. Indeed, WRF was not associated with an increased risk for mortality in patients randomized to spironolactone, and the risk for death or HF hospital stay was markedly attenuated in those receiving active treatment. These data suggest that elevation of creatinine (and worsening of GFR) in the setting of spironolactone therapy has far less prognostic importance than worsening of renal function without inhibiting the renin-angiotensinaldosterone system, a finding that is similar to those seen with ACE inhibition post-MI and in HF (11, 12) . These findings suggest that the reduction in eGFR associated with renin-angiotensin-aldosterone inhibition do not necessarily reflect kidney injury but might result from MRA-induced reduction in blood pressure affecting renal blood flow, a notion that is further supported by the lack of worsening of renal function after an initial relatively early decline seen in both the EPHESUS (13) and RALES studies.
A number of potential mechanisms might explain the benefit of MRAs in the context of renal dysfunction, indepen- Tables 1 and 2 .
Efficacy of Spironolactone by Baseline eGFR and by WRF dent of the potential hemodynamic effects. Up-regulation of mineralocorticoid receptor density and activity in the heart and kidney might play an important role in aldosterone-mediated organ damage (18, 19) . Aldosterone induces proteinuria, glomerular mesangial injury, and tubulointerstitial fibrosis in rat models, and treatment with MRAs prevented renal injury secondary to aldosterone administration (20, 21) . Additionally, the incidence and magnitude of proteinuria or albuminuria are higher among patients with primary aldosteronism compared with patients with essential hypertension (22, 23) . The use of an MRA alone or in combination with ACE inhibition or ARB therapy was shown to produce additive effects to the reduction of proteinuria in small randomized studies, which could suggest that aldosterone might play an important role in causing renal injury (24 -26) . Whether these mechanisms account for the preservation of the benefit of MRAs in HF patients remains unclear, and it is likely that improved outcomes in patients with renal dysfunction are more attributable to a reduction in cardiac fibrosis and remodeling similar to patients with normal renal function. Hyperkalemia is a well-recognized adverse outcome in patients treated with inhibitors of the renin-angiotensin- Adverse Events and Drug Discontinuation During Titration *Variable was defined as hyperkalemia Ͼ5.5 mmol/l or an investigator-reported adverse event (AE), occurring at any time during the trial; †comparison between placebo (PL) and spironolactone (SP) groups within each category of renal function. eGFR ϭ estimated glomerular filtration rate; K ϭ potassium; OR ϭ odds ratio; WRF ϭ worsening renal function.
